FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4324334807> ?p ?o ?g. }

• W4324334807 endingPage "115165" @default.
• W4324334807 startingPage "115165" @default.
• W4324334807 abstract "This exploratory post hoc analysis of two pooled 4-week, phase 3, double-blind, placebo- and active-controlled studies that compared esketamine nasal spray plus a newly initiated oral antidepressant (ESK+AD; n = 310) with a newly initiated oral AD plus placebo nasal spray (AD+PBO; n = 208) in patients with treatment-resistant depression (TRD) examined baseline patient demographic and psychiatric characteristics as potential predictors of response (≥50% reduction from baseline in Montgomery-Åsberg Depression Rating Scale [MADRS] total score) and remission (MADRS total score ≤12) at day 28. Overall, younger age, any employment, fewer failed ADs in the current depressive episode, and reduction in Clinical Global Impression-Severity (CGI-S) score at day 8 were significant positive predictors of response and remission at day 28. Treatment assignment was an important predictor of both response and remission. Patients treated with ESK+AD had 68% and 55% increased odds of achieving response and remission, respectively, versus those treated with AD+PBO. In the ESK+AD group, attainment of response and remission was more likely in patients who were employed, without significant anxiety at baseline, and who experienced a reduction in CGI-S score at day 8. Identification of predictors of response and remission may facilitate identification of those patients with TRD most likely to benefit from ESK+AD. Trial Registration: ClinicalTrials.gov: NCT02417064 (clinicaltrials.gov/ct2/show/NCT02417064) and NCT02418585 (clinicaltrials.gov/ct2/show/NCT02418585)." @default.
• W4324334807 created "2023-03-16" @default.
• W4324334807 creator A5003179564 @default.
• W4324334807 creator A5007020829 @default.
• W4324334807 creator A5016572108 @default.
• W4324334807 creator A5023527028 @default.
• W4324334807 creator A5036810356 @default.
• W4324334807 creator A5039164971 @default.
• W4324334807 creator A5053776875 @default.
• W4324334807 creator A5059028389 @default.
• W4324334807 creator A5071518287 @default.
• W4324334807 creator A5085501292 @default.
• W4324334807 creator A5090970615 @default.
• W4324334807 date "2023-05-01" @default.
• W4324334807 modified "2023-10-01" @default.
• W4324334807 title "Predictors of response and remission in patients with treatment-resistant depression: A post hoc pooled analysis of two acute trials of esketamine nasal spray" @default.
• W4324334807 cites W1912586069 @default.
• W4324334807 cites W1975934950 @default.
• W4324334807 cites W1994672146 @default.
• W4324334807 cites W2018366064 @default.
• W4324334807 cites W2043705607 @default.
• W4324334807 cites W2121528518 @default.
• W4324334807 cites W2138606641 @default.
• W4324334807 cites W2146659162 @default.
• W4324334807 cites W2226243673 @default.
• W4324334807 cites W2320144817 @default.
• W4324334807 cites W2340083175 @default.
• W4324334807 cites W2802678418 @default.
• W4324334807 cites W2912280329 @default.
• W4324334807 cites W2946661342 @default.
• W4324334807 cites W2961020354 @default.
• W4324334807 cites W3027100496 @default.
• W4324334807 cites W3036507891 @default.
• W4324334807 cites W3124230025 @default.
• W4324334807 cites W3183211470 @default.
• W4324334807 cites W3183296242 @default.
• W4324334807 doi "https://doi.org/10.1016/j.psychres.2023.115165" @default.
• W4324334807 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37019044" @default.
• W4324334807 hasPublicationYear "2023" @default.
• W4324334807 type Work @default.
• W4324334807 citedByCount "1" @default.
• W4324334807 countsByYear W43243348072023 @default.
• W4324334807 crossrefType "journal-article" @default.
• W4324334807 hasAuthorship W4324334807A5003179564 @default.
• W4324334807 hasAuthorship W4324334807A5007020829 @default.
• W4324334807 hasAuthorship W4324334807A5016572108 @default.
• W4324334807 hasAuthorship W4324334807A5023527028 @default.
• W4324334807 hasAuthorship W4324334807A5036810356 @default.
• W4324334807 hasAuthorship W4324334807A5039164971 @default.
• W4324334807 hasAuthorship W4324334807A5053776875 @default.
• W4324334807 hasAuthorship W4324334807A5059028389 @default.
• W4324334807 hasAuthorship W4324334807A5071518287 @default.
• W4324334807 hasAuthorship W4324334807A5085501292 @default.
• W4324334807 hasAuthorship W4324334807A5090970615 @default.
• W4324334807 hasBestOaLocation W43243348071 @default.
• W4324334807 hasConcept C118552586 @default.
• W4324334807 hasConcept C126322002 @default.
• W4324334807 hasConcept C139719470 @default.
• W4324334807 hasConcept C142724271 @default.
• W4324334807 hasConcept C156957248 @default.
• W4324334807 hasConcept C15744967 @default.
• W4324334807 hasConcept C162324750 @default.
• W4324334807 hasConcept C203014093 @default.
• W4324334807 hasConcept C204787440 @default.
• W4324334807 hasConcept C27081682 @default.
• W4324334807 hasConcept C2776000289 @default.
• W4324334807 hasConcept C2776867660 @default.
• W4324334807 hasConcept C2777342061 @default.
• W4324334807 hasConcept C2779144063 @default.
• W4324334807 hasConcept C2779177272 @default.
• W4324334807 hasConcept C2780051608 @default.
• W4324334807 hasConcept C2780973058 @default.
• W4324334807 hasConcept C535046627 @default.
• W4324334807 hasConcept C558461103 @default.
• W4324334807 hasConcept C67761136 @default.
• W4324334807 hasConcept C71924100 @default.
• W4324334807 hasConcept C85663871 @default.
• W4324334807 hasConceptScore W4324334807C118552586 @default.
• W4324334807 hasConceptScore W4324334807C126322002 @default.
• W4324334807 hasConceptScore W4324334807C139719470 @default.
• W4324334807 hasConceptScore W4324334807C142724271 @default.
• W4324334807 hasConceptScore W4324334807C156957248 @default.
• W4324334807 hasConceptScore W4324334807C15744967 @default.
• W4324334807 hasConceptScore W4324334807C162324750 @default.
• W4324334807 hasConceptScore W4324334807C203014093 @default.
• W4324334807 hasConceptScore W4324334807C204787440 @default.
• W4324334807 hasConceptScore W4324334807C27081682 @default.
• W4324334807 hasConceptScore W4324334807C2776000289 @default.
• W4324334807 hasConceptScore W4324334807C2776867660 @default.
• W4324334807 hasConceptScore W4324334807C2777342061 @default.
• W4324334807 hasConceptScore W4324334807C2779144063 @default.
• W4324334807 hasConceptScore W4324334807C2779177272 @default.
• W4324334807 hasConceptScore W4324334807C2780051608 @default.
• W4324334807 hasConceptScore W4324334807C2780973058 @default.
• W4324334807 hasConceptScore W4324334807C535046627 @default.
• W4324334807 hasConceptScore W4324334807C558461103 @default.
• W4324334807 hasConceptScore W4324334807C67761136 @default.
• W4324334807 hasConceptScore W4324334807C71924100 @default.

• next